All News
FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h
sheila RHEUMarampa ( View Tweet)
TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205
Jiha Lee JihaRheum ( View Tweet)
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206
Jiha Lee JihaRheum ( View Tweet)
RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA
-Primary endpoint DAS28-CRP change wk12
-2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01
-ACR20/50/70 + CDAI LDA all improved vs PBO
-hsCRP reduction across all dose arms
-69% CDAI LDA by wk14
-wk 28 extension shows https://t.co/AMfmSded0D
Aurelie Najm AurelieRheumo ( View Tweet)
A new MoA that does not meet it's primary endpoint in RA
SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib
ACR20 wk12 NOT significantly diff vs PBO
~48.5–61.8% across doses vs 52.3% PBO
Secondary BALI 200 mg QD:
ACR50: 36.9% vs 18.5% (nominal p=0.0179)
Mechanistic https://t.co/hmZ93JisiO
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#OP0225 at #EULAR2026: In this nationwide French cohort, patients with IMIDs had nearly 2x risk of HPV-related cancers or severe dysplasia versus matched controls. Risk was particularly increased in SLE, reinforcing the importance of HPV vaccination and screening. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Which ‘CAR’ to drive in #SLE?
Comparison of #CD19 #CAR-T
#allogenic vs #Autologous
➡️ comparing #molecular #responses from 2 #lupus studies N=12
Both improved cytokine signatures
For
#IFN & #neutrophils
Results similar not identical
?either
#POS0678 #EULAR2026 @RheumNow https://t.co/Lcpv3qJ6tU
Links:
Janet Pope Janetbirdope ( View Tweet)
Rheumatology Shortage Cliff in Australia & USA
Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States. The Australian Rheumatology Association's 2025 Workforce Report warns that the nation faces a significant https://t.co/qVziLM25JR
Dr. John Cush RheumNow ( View Tweet)
#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
JAKi vs TNFi in #RA: Swedish registry (n=21,314) shows JAKi carries ↑ risk of hospitalized infections (IRR 1.23) and ~2x viral infection risk after accounting for treatment discontinuation. Treatment selection matters. @RheumNow #EULAR2026 POS0070
Jiha Lee JihaRheum ( View Tweet)
Do we really need yet another JAKi?
COURAGE-RA RCT phIII JAK1-selective Zemprocitinib RA bDMARDs IR
Primary endpoint ACR20 at wk24
79.1% vs 39.7% PBO (p<0.0001)
wk24 ACR50: 55.8% vs 22.0%
wk 24 DAS28-CRP ≤3.2: 67.0% vs 23.4%
No new safety signal
Looks very similar to other https://t.co/b0RMBWl4Xx
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Low-dose blinatumomab in multidrug-resistant RA
15 pts 96h cycles CD3×CD19 T-cell engager
DAS28-CRP: 4.8 → 2.4
3 mo ACR20 100% ACR50 73% ACR70 53%
DAS28 remission 33%
But... only transient efficacy with
93% relapse after stopping treatment
Authors highlight response to https://t.co/GCS6774tJt
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2026 OP0221 Can we refine response measure in #lupusnephritis RCT? Asia Pacific cohort: construct validity of TRM-SLE definition: 1)RCT entry threshold uPCR >1g/g; 2)clinically meaningful response >50% improvement in UPCR; 3)stricter complete response UPCR<0.2g/g @RheumNow https://t.co/dlErgyFMZP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP0223 at #EULAR2026: Not every lupus nephritis patient may need upfront triple therapy. Using EULAR 2025 prognostic factors, triple therapy significantly improved complete renal response only in high-risk patients, supporting more precision-based treatment approach. @RheumNow https://t.co/F8Kn23YjNr
Mrinalini Dey DrMiniDey ( View Tweet)
Ivarmacitinib (selective oral JAKi) in active nr-axSpA:
This ph3 RCT showed that Ivarmacitinib 4mg significantly improved s/sxs & dse act vs. PBO at wk 12 (39.7% vs 24.8%; P=0.0057) and maintained until wk 24
Interesting. A new JAKi option for axSpA
OPO237 @RheumNow #EULAR2026 https://t.co/bxbO8GfegP
Links:
sheila RHEUMarampa ( View Tweet)
#OP0222 at #EULAR2026: ReBioLup highlights the disconnect between proteinuria & histopathological activity in lupus nephritis. 73% of patients with persistent histologic activity at 12 months still met criteria for complete clinical response. @RheumNow https://t.co/VxgT6812VO
Mrinalini Dey DrMiniDey ( View Tweet)
ASAS-SPARTAN revised #axSpA classification criteria have hug specificity (>94%) but lower sensitivity than the 2009 criteria, excluding ~27% of patients classified by the older criteria Abstr OP239 @RheumNow #EULAR2026 https://t.co/vGJN8eEKKh
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
